1. Home
  2. SPRB vs JAGX Comparison

SPRB vs JAGX Comparison

Compare SPRB & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRB
  • JAGX
  • Stock Information
  • Founded
  • SPRB 2014
  • JAGX 2013
  • Country
  • SPRB United States
  • JAGX United States
  • Employees
  • SPRB N/A
  • JAGX N/A
  • Industry
  • SPRB Medicinal Chemicals and Botanical Products
  • JAGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SPRB Health Care
  • JAGX Health Care
  • Exchange
  • SPRB Nasdaq
  • JAGX Nasdaq
  • Market Cap
  • SPRB 15.7M
  • JAGX 12.9M
  • IPO Year
  • SPRB 2020
  • JAGX N/A
  • Fundamental
  • Price
  • SPRB $0.33
  • JAGX $0.45
  • Analyst Decision
  • SPRB Hold
  • JAGX
  • Analyst Count
  • SPRB 7
  • JAGX 0
  • Target Price
  • SPRB $2.17
  • JAGX N/A
  • AVG Volume (30 Days)
  • SPRB 300.3K
  • JAGX 405.5K
  • Earning Date
  • SPRB 03-21-2025
  • JAGX 03-31-2025
  • Dividend Yield
  • SPRB N/A
  • JAGX N/A
  • EPS Growth
  • SPRB N/A
  • JAGX N/A
  • EPS
  • SPRB N/A
  • JAGX N/A
  • Revenue
  • SPRB $7,101,000.00
  • JAGX $10,480,000.00
  • Revenue This Year
  • SPRB N/A
  • JAGX $18.18
  • Revenue Next Year
  • SPRB N/A
  • JAGX $40.06
  • P/E Ratio
  • SPRB N/A
  • JAGX N/A
  • Revenue Growth
  • SPRB N/A
  • JAGX N/A
  • 52 Week Low
  • SPRB $0.33
  • JAGX $0.44
  • 52 Week High
  • SPRB $1.29
  • JAGX $21.60
  • Technical
  • Relative Strength Index (RSI)
  • SPRB 27.09
  • JAGX 26.15
  • Support Level
  • SPRB $0.34
  • JAGX $0.57
  • Resistance Level
  • SPRB $0.36
  • JAGX $0.60
  • Average True Range (ATR)
  • SPRB 0.03
  • JAGX 0.07
  • MACD
  • SPRB -0.01
  • JAGX -0.02
  • Stochastic Oscillator
  • SPRB 2.70
  • JAGX 2.14

About SPRB Spruce Biosciences Inc.

Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Share on Social Networks: